Vasoactive Intestinal Peptide (VIP)

Drug Overview

Vasoactive Intestinal Peptide (VIP) is a naturally occurring neuropeptide and hormone with broad physiological functions. As a therapeutic agent, it is investigated for its potent immunomodulatory and anti-inflammatory properties.

• Generic Name: Vasoactive Intestinal Peptide
• US Brand Names: Investigational; no FDA-approved brand names currently.
• Drug Class: Neuropeptide / Immunomodulator
• Route of Administration: Intravenous (IV), Inhalation (Investigational)
• FDA Approval Status: Not FDA-approved for therapeutic use. Primarily used in clinical research.

Mechanism of Action

Vasoactive Intestinal Peptide (VIP) achieves its physiological effects by interacting with specific G-protein-coupled receptors, namely VPAC1 and VPAC2. These receptors are ubiquitously located on diverse cell types such as immune cells, epithelial cells, and smooth muscle.

• Molecular Target: VPAC1 and VPAC2 receptors.
• Cellular Impact: Receptor activation stimulates adenylate cyclase, increasing intracellular cyclic AMP (cAMP) levels.
• Result: Elevated cAMP acts as a potent second messenger, leading to:
  1. Immunomodulation: Shifts the immune response from a pro-inflammatory (Th1) to an anti-inflammatory (Th2) profile. Inhibits T-cell proliferation and cytokine production (e.g., TNF-α, IL-6) while promoting regulatory T-cell (Treg) function.
  2. Vasodilation: Relaxes smooth muscle in blood vessels and airways.
  3. Cytoprotection: Reduces apoptosis and protects epithelial barrier function.
• Tissue Affinity: VIP receptors are highly expressed in the lungs, gastrointestinal tract, and central nervous system, allowing for targeted effects in these organs.

FDA-Approved Clinical Indications

Vasoactive Intestinal Peptide (VIP) does not currently hold approval from the U.S. Food and Drug Administration (FDA) for any specific clinical indication or therapeutic use. As a result, it is not available as a standard prescription medication for general medical treatment.

Investigational/Therapeutic Areas of Focus:

• Acute Respiratory Distress Syndrome (ARDS) / Lung Injury: For its anti-inflammatory and barrier-protective effects in the lungs.
• Autoimmune Diseases: Such as rheumatoid arthritis and Crohn’s disease, due to their immunomodulatory action.
• Pulmonary Arterial Hypertension (PAH): Investigated for its vasodilatory and anti-proliferative effects on pulmonary vasculature.
• Neuroinflammatory Conditions: Including sepsis-associated encephalopathy and multiple sclerosis.

Dosage and Administration Protocols

Since this medication remains classified as an investigational agent, no standardized dosing regimen currently exists. Instead, administration protocols differ significantly based on the specific clinical trial and the condition being targeted.

Representative Investigational Dosing (from published studies):

Clinical Efficacy and Research Outcomes

Recent pre-clinical and early-phase clinical studies conducted between 2020 and 2025 demonstrate VIP’s promising therapeutic potential; however, robust efficacy data from large-scale trials remain necessary to fully confirm these findings.

• ARDS and Sepsis: Animal models and small human studies suggest VIP infusion can significantly reduce levels of pro-inflammatory cytokines (e.g., IL-6) and improve oxygenation indices. Early-phase trials report trends toward reduced ventilator days and mortality, but these findings require confirmation in larger, controlled studies.
• Autoimmune and Inflammatory Diseases: In models of rheumatoid arthritis and colitis, VIP administration reduces disease severity scores, leukocyte infiltration, and joint/tissue destruction. Its action on Tregs is a key mechanism being exploited in immunotherapy approaches.
• Pulmonary Hypertension: Inhaled VIP has been shown in studies to improve hemodynamic parameters (e.g., reduced pulmonary vascular resistance) and exercise capacity, with effects lasting several hours post-inhalation.
• Comparative Data: As a naturally occurring immunomodulator, VIP is compared to biologics like TNF-α inhibitors. Its broad receptor-mediated effects on multiple immune pathways offer a potentially unique mechanism, but its short half-life remains a pharmacokinetic challenge.

Safety Profile and Side Effects

Current safety profiles rely on phase I and II clinical trial data, noting that this specific peptide does not carry any assigned Black Box Warnings from regulatory bodies at present.

Black Box Warning:

• There is currently no Black Box Warning assigned to Vasoactive Intestinal Peptide (VIP). This is because VIP is an investigational agent and has not been approved by the U.S. Food and Drug Administration (FDA) for any therapeutic use. A Black Box Warning is the FDA’s most stringent safety alert and is only issued for approved prescription drugs with serious or life-threatening risks.

Common Side Effects (Reported in trials):

• Cardiovascular: Transient facial flushing, mild hypotension due to vasodilation.
• Gastrointestinal: Nausea.
• Respiratory (with inhalation): Cough, throat irritation.
• Other: Headache, dizziness.

Serious Adverse Events & Considerations:

1. Hypotension: The vasodilatory effect can cause significant drops in blood pressure, requiring careful monitoring during IV infusion, especially in hemodynamically unstable patients.
2. Immunosuppression: Its intended immunomodulatory effect may theoretically increase susceptibility to infections, though this has not been a prominent finding in limited trials.
3. Tachyphylaxis: Potential for decreased response with continuous administration, necessitating optimized dosing intervals.

Connection to Stem Cell & Regenerative Medicine

VIP creates a tolerogenic immune environment and actively promotes tissue repair, positioning it as a strong candidate for combination with regenerative strategies to enhance healing and improve overall therapeutic efficacy.

• Stem Cell Transplantation and Engraftment: Research indicates VIP can enhance the survival and function of mesenchymal stem cells (MSCs) by protecting them from inflammatory apoptosis. In transplant models, co-administration of VIP with MSCs has shown improved engraftment and greater efficacy in reducing graft-versus-host disease (GVHD) or treating inflammatory conditions like bronchopulmonary dysplasia.
• Tissue Regeneration and Repair: Through its anti-inflammatory and anti-fibrotic actions, VIP may help create a favorable microenvironment for endogenous stem and progenitor cells to facilitate repair in injured lungs, intestines, and nervous tissue. It is being studied as an adjunct to cell-based therapies for organ fibrosis and stroke.

Patient Management and Practical Recommendations

Pre-Treatment

• Cardiovascular Assessment: Evaluate baseline blood pressure and cardiac stability.
• Laboratory Tests: Baseline inflammatory markers (e.g., CRP, IL-6), complete blood count, and metabolic panel.
• Informed Consent: Thorough discussion of the investigational nature of the therapy.

During Treatment

• Monitoring: Continuous monitoring of vital signs (especially blood pressure) during IV infusion. Monitor for signs of infection.
• Administration: IV administration requires an infusion pump. Inhaled formulations require proper nebulizer technique.
• Hydration: Ensure euvolemia to mitigate hypotensive effects.

Do’s and Don’ts

• DO: Report symptoms of significant dizziness, fainting, or rapid heart rate immediately.
• DO: Adhere strictly to the administration protocol defined by the clinical trial.
• DON’T: Self-administer or adjust the infusion/inhalation rate.
• DON’T: Use concurrently with other potent vasodilators or antihypertensives without close medical supervision.

Disclaimer

This guide is for informational and research-oriented purposes only and is intended for healthcare professionals and clinical researchers. Vasoactive Intestinal Peptide (VIP) is an investigational agent and is not approved for clinical use. This content does not constitute medical advice. All treatment within a clinical setting must be conducted under approved investigational protocols and under the direction of qualified principal investigators